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ABSTRACT
Bullous pemphigoid is an autoimmune blistering
condition mediated by autoantibodies1. It is categorized
as an uncommon disorder 2-4 , with an estimated
incidence of 2.4-21.7 cases per million2-6 but carries
significant morbidity and mortality, warranting clinical
awareness and investigation7,8. A number of medications
have been implicated in the development of bullous
pemphigoid including loop diuretics, ace inhibitors, and
anti-epileptic drugs.
This is a case report of carbamazepine-induced bullous
pemphigoid in a 49-year-old male after taking the
medication for almost 30 years. Diagnosis of bullous
pemphigoid was based on biopsy histology and
immunofluorescence, as well as the presence of BP
180 antibody. Clinical features of extensive rash and
bullae were present on dermatological exam. Upon
discontinuation of carbamazepine and appropriate
treatment of bullous pemphigoid, the patient’s condition
improved. A thorough analysis of the patient’s history
and medications did not reveal any other potential
triggers of bullous pemphigoid.
The only two previous reports of an association between
carbamazepine and bullous pemphigoid are limited by
lack of immunologic evidence of diagnosis or the
identification of a specific causative agent. To address
these limitations, we describe what is to our knowledge,
the first reported case of clearly documented association
between carbamazepine and bullous pemphigoid.

BACKGROUND
Bullous pemphigoid is an autoimmune blistering
condition mediated by autoantibodies1 . It is categorized
as an uncommon disorder2-4 , with an estimated incidence
of 2.4-21.7 cases per million 2-6 . Bullous pemphigoid
carries significant morbidity and mortality. Mortality
rates in the US range from 11-23%7. Risks associated with
this condition include dehydration, superimposed
infection, and scarring 8 . Bullous pemphigoid may
develop spontaneously or be triggered by infection or
medication. A number of medications have been
implicated in the development of bullous pemphigoid

18 | The Medicine Forum, Volume 22 5

including loop diuretics, ace inhibitors, and anti-epileptic
drugs9-11 . There are 2 case reports available which claim
an association between BP and carbamazepine12,13 .

CASE
A 49-year-old male, with a past medical history
significant for cerebral palsy and seizure disorder
well-controlled on carbamazepine, presented with
worsening bullous pemphigoid diagnosed at an
outside hospital. He was admitted due to worsening of
his condition despite topical and oral corticosteroid
treatment. The rash presented as blistering on his trunk
and all four extremities. There was no mucosal
involvement. The patient and his family denied any
new medications, foods, illnesses, or environmental
exposures. Dermatological exam noted tense bullae
filled with clear to straw-colored fluid primarily on the
trunk and thighs but also on the more distal extremities.
Ruptured bullae with overlying crust were also present,
especially on the hands and feet. Nikolsky sign was
negative.
The diagnosis of bullous pemphigoid was confirmed
with the presence of linear basement membrane
deposits on immunofluorescence. Direct immunofluorescence analysis of a skin biopsy demonstrated
intralesional IgG deposition and linear immunofluorescence at the dermal-epidermal junction of lesions.
Additionally, BP 180 antibody testing was positive with
a serum concentration of 126 U/mL.
The patient’s home medication list, which included
aspirin, lorazepam, trazodone, and carbamazepine,
was reviewed to identify potential causes of bullous
pemphigoid other than carbamazepine. Other than
carbamazepine, none of these medications are
associated with serious skin conditions or bullous
p e m p h i g o i d . T h e refo re, c a r b a m aze p i n e w as
discontinued and switched to levetiracetam for seizure
prophylaxis. After the removal of carbamazepine and
initiation of rituximab for treatment-refractory bullous
pemphigoid, no new lesions developed. Six weeks
after discharge the patient’s condition continued to
improve.

Figure 1: Physical exam findings of widespread bullous skin eruption. Multiple tense bullae present on trunk and ruptured bullae present on distal extremities.

DISCUSSION
Carbamazepine is an anticonvulsant that is associated
with serious, even fatal dermatologic reactions, including
Stevens-Johnson Syndrome and Toxic Epidermal
Necrolysis14 . Autoimmune blistering conditions such as
bullous pemphigoid are not among the known skin
reactions caused by carbamazepine. There are only two
reports of an association between carbamazepine and

bullous pemphigoid 12,1 3 . The first describes the
development of bullous pemphigoid after carbamazepine
overdose. However, direct immunofluorescence was
not conducted and serum studies were reported to be
negative. The second report describes the development
of bullous pemphigoid in a patient taking carbamazepine,
zonisamide and minocycline. Lesional biopsy plus direct
and indirect immunofluorescence indicated bullous
pemphigoid as the diagnosis. However, clinical
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improvement was noted after the removal of all three
medications and reintroduction was not attempted
with any of the implicated medications. Moreover,
results of drug-induced lymphocyte stimulation tests
for carbamazepine, zonisamide and minocycline
hydrochloride were negative.
This study has overcome the limitations of previous
reports. Bullous pemphigoid was confirmed clinically
with improvement after the removal of carbamazepine,
immunohistologically with biopsy and direct immunofluorescence, and serologically with the identification of
BP 180 antibodies. The probable relationship between
the adverse effect of bullous pemphigoid and
carbamazepine was also indicated with use of the
Naranjo Adverse Drug Reaction Probability Scale, which
is consistent with our conclusion that carbamazepine
was the likely cause of bullous pemphigoid 15 . The
primary limitation of this study is that reintroduction of
carbamazepine was not attempted.
Thus, we present this as the first report of proven bullous
pemphigoid in association with carbamazepine use. The
goal of this report is to create awareness of this
association in order to encourage clinical vigilance and
the reporting of similar findings in the future.
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